StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
603363.SS$3.29+1.86%
Fair $3.29+0.0%

603363.SS

Fujian Aonong Biological Technology Group Incorporation Limited

Consumer Defensive / Farm ProductsShanghai

$3.29

+0.06 (+1.86%)

Fairly Valued+0.0%Fair Value $3.29Fund rank 22/100 · Data gapFallback financials|
SA 22/D
F-Score: 6/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 16%

FCF escenarios

weak_data · normalized FCF $-77.0M · quality 33.7/100

Data gap 22/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 11/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

22/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 3 consecutive years ROE is 2.5%, below the 5% threshold
Thesis & Journal · 603363.SSLocal privado en este navegador · Fujian Aonong Biological Technology Group Incorporation Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$8.6B

P/E

109.7x

↑

EV/EBITDA

14.1x

↑

ROE

2.5%

↓

Gross Margin

6.3%

↓

Debt/Equity

0.74

↑
52-Week Range$3
$3$6

TradingView lightweight chart

603363.SS price, volumen y niveles de valoración

Último $3.290Periodo -38.0%
Fair value: $3.290

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-26.8%

FCF CAGR

—

FCF margin

-0.9%

FCF / Net income

-0.99x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $8.47B · net income $77.6M · FCF $-77.0M

2022-FY → 2025-FY

Gross margin

6.3%+1.9% pts

Operating margin

-0.5%+0.7% pts

Net margin

0.9%+5.7% pts

FCF margin

-0.9%+3.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$8.47B$8.47B$8.76B$19.46B$21.61B
Net Income$77.6M$77.6M$579.3M$-3.65B$-1.04B
EBITDA$721.7M$721.7M$1.57B$-1.90B$500.4M
EPS0.030.030.67-4.21-1.34
Gross Margin6.3%6.3%4.5%-4.7%4.4%
Operating Margin-0.5%-0.5%-8.5%-10.9%-1.2%
Net Margin0.9%0.9%6.6%-18.8%-4.8%
Balance Sheet
Debt/Equity0.740.741.13-8.363.58
Current Ratio0.930.93———
Cash Flow
Free Cash Flow$-77.0M$-77.0M$-379.5M$472.2M$-835.3M
Returns
ROE2.5%2.5%22.6%379.1%-41.4%
Valuation
P/E109.67109.675.00——
EV/EBITDA14.0614.062.82—36.09
P/B2.722.721.13—3.91
Growth & Yield
Revenue Growth-3.3%-3.3%-55.0%-10.0%—
EPS Growth-95.5%-95.5%115.9%-214.2%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

113.5%

muy exigente

EPS terminal req.

$0.29

Spread vs growth

-209.0%

5Y implied EPS CAGR

63.8%

muy exigente

EPS terminal req.

$0.35

Spread vs growth

-159.3%

10Y implied EPS CAGR

34.2%

muy exigente

EPS terminal req.

$0.57

Spread vs growth

-129.7%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -18.6%

Total return

-18.6%

Start / end P/E

6.0x → 109.7x

EPS bridge

0.67 → 0.03

Residual

-1641.8%

EPS growth-95.5%
Multiple rerating+1718.7%
Dividend+0.0%
Residual / FX / buybacks / cross-term-1641.8%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.